Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Daratumumab Retreatment Leads to Responses in Relapsed/Refractory Myeloma

June 5th 2024

Retreatment with daratumumab-based regimens led to a similar ORR vs initial daratumumab treatment in relapsed/refractory myeloma.

Updated Analysis From MajesTEC-1 Confirms CRS Reduction With Prophylactic Tocilizumab in Relapsed/Refractory Myeloma

June 5th 2024

Updated Analysis from Phase 1/2 MajesTEC-1 trial support the use of prophylactic tocilizumab to reduce the risk of cytokine release syndrome associated with outpatient administration of teclistamab.

Dr Landgren on the Rationale for Utilizing MRD as a Clinical Trial End Point in Myeloma

June 4th 2024

Ola Landgren, MD, PhD, discusses the background for utilizing MRD as a clinical trial end point when evaluating multiple myeloma treatment.

D-VRd Boosts MRD-Negativity Rates in Newly Diagnosed, Transplant-Eligible Multiple Myeloma

June 4th 2024

Daratumumab plus VRd increased rates of MRD negativity in newly diagnosed, transplant-eligible multiple myeloma.

Isa-VRd Prolongs PFS in Newly Diagnosed, Transplant-Ineligible Multiple Myeloma

June 4th 2024

Isatuximab plus VRd produced a statistically significant improvement in PFS vs VRd in newly diagnosed, transplant-ineligible multiple myeloma.

Dr Facon on the Efficacy of Isa-VRd in Newly Diagnosed Multiple Myeloma

June 3rd 2024

Thierry Facon, MD, discusses findings from the phase 3 IMROZ trial investigating Isa-VRd in patients with newly diagnosed multiple myeloma.

CRS, ICANS Incidence Reduced to Zero Following Tocilizumab, Teclistamab Administration in R/R Multiple Myeloma

June 3rd 2024

Tocilizumab plus teclistamab step-up dosing showed efficacy and a mainly mild safety profile in patients with relapsed/refractory multiple myeloma.

Belantamab Mafodotin Plus BVd Produces PROs Comparable to DVd in Relapsed/Refractory Multiple Myeloma

June 3rd 2024

Treatment with BVd elicited PROs comparable with those who were treated with DVd in relapsed/refractory multiple myeloma.

Belantamab Mafodotin Significantly Extends PFS vs Daratumumab in Myeloma

June 2nd 2024

Belantamab mafodotin plus bortezomib and dexamethasone improved median progression-free survival vs daratumumab plus bortezomib and dexamethasone in relapsed/refractory multiple myeloma.

Belantamab Mafodotin Plus Pd Elicits PFS Benefit in R/R Myeloma

June 2nd 2024

Belantamab mafodotin plus BPd improved PFS vs PVd in relapsed/refractory multiple myeloma.

Reviewing the Latest in Breast Cancer and Myeloma: Drs Tarantino and Raje

June 2nd 2024

OncLive® will be LIVE with OncLive® News Network: On Location at the 2024 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference

Revisit Every OncLive On Air Episode From May 2024

May 30th 2024

In case you missed any, below is a recap of every OncLive On Air episode that aired in May 2024.

Dr Landgren on the Utility of MRD as an End Point in Multiple Myeloma Trials

May 29th 2024

C. Ola Landgren, MD, PhD, discusses the utility of minimal residual disease as an end point in clinical trials for the treatment of multiple myeloma.

Dr Baljevic on the PERSEUS Trial in Untreated Multiple Myeloma

May 28th 2024

Muhamed Baljevic, MD, FACP, discusses the phase 3 PERSEUS trial in patients with previously untreated multiple myeloma.

Data for Quadruplet Therapies Could Alter Frontline SOC for Transplant-Ineligible Multiple Myeloma

May 28th 2024

Muhamed Baljevic, MD, FACP, discusses the investigation of frontline quadruplet therapies in transplant-ineligible multiple myeloma.

FDA Grants Priority Review to Isatuximab Combo for Newly Diagnosed, Transplant-Ineligible Myeloma

May 27th 2024

The FDA granted priority review to the sBLA for isatuximab plus bortezomib/lenalidomide/dexamethasone for newly diagnosed, transplant-ineligible myeloma.

First-Line Quadruplet Regimens Continue to Enhance Outcomes in Myeloma

May 25th 2024

Muhamed Baljevic, MD, FACP, discusses the evolution of quadruplet combination therapies in frontline multiple myeloma.

Weighing the Benefits and Limitations of CAR T-Cell Therapy and Bispecific Antibodies in Multiple Myeloma

May 24th 2024

James Ignatz-Hoover, MD, PhD, discusses the evolving use of CAR T-cell therapies and bispecific antibodies in multiple myeloma.

Dr Baljevic on Key Considerations for Treatment Selection in Newly Diagnosed Multiple Myeloma

May 23rd 2024

Muhamed Baljevic, MD, discusses the consideration of patient comorbidities and preferences during treatment selection in newly diagnosed myeloma.

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

May 23rd 2024

Experts from across oncology specialties discuss the abstracts and presentations they are most looking forward to seeing at the 2024 ASCO Annual Meeting.